FACEPHI BIOMETRIA SA (ALPHI.PA) Stock Fundamental Analysis
Europe - Euronext Paris - EPA:ALPHI - ES0105029005 - Common Stock
2.64 EUR
+0.01 (+0.38%)
Taking everything into account, ALPHI scores 2 out of 10 in our fundamental rating. ALPHI was compared to 105 industry peers in the Software industry. Both the profitability and financial health of ALPHI have multiple concerns. ALPHI is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year ALPHI has reported negative net income.
ALPHI had a positive operating cash flow in the past year.
ALPHI had negative earnings in 4 of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: ALPHI reported negative operating cash flow in multiple years.
1.2 Ratios
ALPHI's Return On Assets of -17.78% is on the low side compared to the rest of the industry. ALPHI is outperformed by 84.76% of its industry peers.
ALPHI's Return On Equity of -46.79% is on the low side compared to the rest of the industry. ALPHI is outperformed by 81.90% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -17.78% | ||
| ROE | -46.79% | ||
| ROIC | N/A |
ROA(3y)-7.9%
ROA(5y)-7.67%
ROE(3y)-20.34%
ROE(5y)-18.76%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ALPHI has a Gross Margin of 51.21%. This is in the lower half of the industry: ALPHI underperforms 72.38% of its industry peers.
ALPHI's Gross Margin has declined in the last couple of years.
ALPHI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 51.21% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-20.32%
GM growth 5Y-11.24%
2. Health
2.1 Basic Checks
ALPHI does not have a ROIC to compare to the WACC, probably because it is not profitable.
ALPHI has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ALPHI has been increased compared to 5 years ago.
Compared to 1 year ago, ALPHI has an improved debt to assets ratio.
2.2 Solvency
ALPHI has an Altman-Z score of 1.11. This is a bad value and indicates that ALPHI is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 1.11, ALPHI is doing worse than 72.38% of the companies in the same industry.
ALPHI has a Debt/Equity ratio of 0.05. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.05, ALPHI is in the better half of the industry, outperforming 76.19% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.11 |
ROIC/WACCN/A
WACC8.53%
2.3 Liquidity
ALPHI has a Current Ratio of 1.07. This is a normal value and indicates that ALPHI is financially healthy and should not expect problems in meeting its short term obligations.
ALPHI has a worse Current ratio (1.07) than 64.76% of its industry peers.
ALPHI has a Quick Ratio of 1.07. This is a normal value and indicates that ALPHI is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of ALPHI (1.07) is worse than 62.86% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.07 | ||
| Quick Ratio | 1.07 |
3. Growth
3.1 Past
The earnings per share for ALPHI have decreased strongly by -54.17% in the last year.
Looking at the last year, ALPHI shows a quite strong growth in Revenue. The Revenue has grown by 17.17% in the last year.
ALPHI shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 28.76% yearly.
EPS 1Y (TTM)-54.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-550%
Revenue 1Y (TTM)17.17%
Revenue growth 3Y30.13%
Revenue growth 5Y28.76%
Sales Q2Q%13.33%
3.2 Future
ALPHI is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 29.14% yearly.
ALPHI is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 19.34% yearly.
EPS Next Y104%
EPS Next 2Y50.67%
EPS Next 3YN/A
EPS Next 5Y29.14%
Revenue Next Year25.74%
Revenue Next 2Y24.47%
Revenue Next 3Y19.64%
Revenue Next 5Y19.34%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
ALPHI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
With a Price/Forward Earnings ratio of 194.17, ALPHI can be considered very expensive at the moment.
ALPHI's Price/Forward Earnings ratio is a bit more expensive when compared to the industry. ALPHI is more expensive than 69.52% of the companies in the same industry.
ALPHI is valuated expensively when we compare the Price/Forward Earnings ratio to 23.35, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 194.17 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
A more expensive valuation may be justified as ALPHI's earnings are expected to grow with 50.67% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y50.67%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for ALPHI!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
EPA:ALPHI (12/30/2025, 7:00:00 PM)
2.64
+0.01 (+0.38%)
Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupSoftware & Services
GICS IndustrySoftware
Earnings (Last)
Earnings (Next)
Inst Owners28.04%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap68.06M
Revenue(TTM)29.00M
Net Income(TTM)-8.89M
Analysts82.5
Price Target3.56 (34.85%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.08%
PT rev (3m)17.7%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-7.34%
Revenue NY rev (3m)-17.99%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 194.17 | ||
| P/S | 2.35 | ||
| P/FCF | N/A | ||
| P/OCF | 94.53 | ||
| P/B | 3.58 | ||
| P/tB | 9.72 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.37
EYN/A
EPS(NY)0.01
Fwd EY0.52%
FCF(TTM)-0.18
FCFYN/A
OCF(TTM)0.03
OCFY1.06%
SpS1.12
BVpS0.74
TBVpS0.27
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -17.78% | ||
| ROE | -46.79% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 51.21% | ||
| FCFM | N/A |
ROA(3y)-7.9%
ROA(5y)-7.67%
ROE(3y)-20.34%
ROE(5y)-18.76%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-20.32%
GM growth 5Y-11.24%
F-Score5
Asset Turnover0.58
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 93.92% | ||
| Cap/Sales | 18.1% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.07 | ||
| Quick Ratio | 1.07 | ||
| Altman-Z | 1.11 |
F-Score5
WACC8.53%
ROIC/WACCN/A
Cap/Depr(3y)134.94%
Cap/Depr(5y)175.33%
Cap/Sales(3y)22.27%
Cap/Sales(5y)23.55%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-54.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-550%
EPS Next Y104%
EPS Next 2Y50.67%
EPS Next 3YN/A
EPS Next 5Y29.14%
Revenue 1Y (TTM)17.17%
Revenue growth 3Y30.13%
Revenue growth 5Y28.76%
Sales Q2Q%13.33%
Revenue Next Year25.74%
Revenue Next 2Y24.47%
Revenue Next 3Y19.64%
Revenue Next 5Y19.34%
EBIT growth 1Y-23.98%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year168.63%
EBIT Next 3Y52.17%
EBIT Next 5Y44.47%
FCF growth 1Y49.72%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-15.29%
OCF growth 3YN/A
OCF growth 5YN/A
FACEPHI BIOMETRIA SA / ALPHI.PA FAQ
What is the fundamental rating for ALPHI stock?
ChartMill assigns a fundamental rating of 2 / 10 to ALPHI.PA.
What is the valuation status of FACEPHI BIOMETRIA SA (ALPHI.PA) stock?
ChartMill assigns a valuation rating of 1 / 10 to FACEPHI BIOMETRIA SA (ALPHI.PA). This can be considered as Overvalued.
What is the profitability of ALPHI stock?
FACEPHI BIOMETRIA SA (ALPHI.PA) has a profitability rating of 1 / 10.
What is the expected EPS growth for FACEPHI BIOMETRIA SA (ALPHI.PA) stock?
The Earnings per Share (EPS) of FACEPHI BIOMETRIA SA (ALPHI.PA) is expected to grow by 104% in the next year.
Is the dividend of FACEPHI BIOMETRIA SA sustainable?
The dividend rating of FACEPHI BIOMETRIA SA (ALPHI.PA) is 0 / 10 and the dividend payout ratio is 0%.